Terms of the agreement, which include six million restricted shares to NanoTherapies, are subject to formal approval by the managing member and governing board of directors of NanoTherapies. In addition, a full audit of NanoTherapies needs to be completed as well for a binding agreement.
Recently, Cancer Therapeutics announced the completion of a 25% stake in NanoTherapies, making it the company's first acquisition.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index